Jazz Pharmaceuticals Plc
A global biopharmaceutical company focused on rare diseases, Jazz Pharmaceuticals makes medicines for sleep disorders, epilepsy, and cancer. Its flagship products include Xywav for narcolepsy, Epidiolex for rare epilepsies, and the newer oncology drugs Ziihera and Modeyso. Founded in 2003 by Bruce Cozadd, the company took its name from the idea of jazz improvisation — innovating freely while staying grounded in a shared structure, much like musicians jamming together on stage.
Granted 25.3K · Bought 101.6K
Granted 520.8K · Sold 295.9K
Granted 170.7K · Sold 8.6K
Granted 107.3K · Sold 18.5K
Granted 50.9K · Bought 12.0K
Granted 27.0K
Granted 129.8K · Sold 79.1K
Granted 81.2K · Sold 28.2K
Granted 17.4K · Sold 5.0K
Granted 20.4K · Sold 9.6K
Granted 39.7K · Sold 9.0K
Granted 10.7K · Sold 6.0K
Granted 12.9K · Sold 9.3K
Granted 24.3K · Sold 13.4K
Granted 24.3K · Sold 13.7K
Granted 12.9K · Sold 2.8K
Granted 13.6K · Sold 10.4K
Granted 5.6K · Sold 2.3K
Granted 11.9K · Sold 5.2K
Granted 12.9K · Sold 3.6K
Granted 12.9K · Sold 4.7K
Granted 16.3K · Sold 10.6K
Granted 7.2K
Granted 8.7K
Granted 35.0K · Sold 31.8K
Granted 1.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Mulligan SeamusDirector · 11 transactions | — | 1.28M | 25.3K | 101.6K | — |
| Cozadd Bruce CDirector · 122 transactions | +20.3% | 372.7K | 520.8K | — | 295.9K |
| Gala Renee DPresident & CEO · 27 transactions | +500.4% | 152.2K | 170.7K | — | 8.6K |
| Iannone RobertEVP, Global Head of R&D & CMO · 24 transactions | +205.5% | 88.9K | 107.3K | — | 18.5K |
| Johnson Philip LEVP & Chief Financial Officer · 7 transactions | — | 59.6K | 50.9K | 12.0K | — |
| Swisher Daniel N JRPresident and COO · 6 transactions | +10.1% | 55.0Kas of Mar 2023 | 27.0K | — | — |
| Patil Neena MEVP & Chief Legal Officer · 47 transactions | +104.3% | 51.5K | 129.8K | — | 79.1K |
| Pearce SamanthaEVP, Chief Commercial Officer · 42 transactions | +320.4% | 50.3K | 81.2K | — | 28.2K |
| O'Keefe Kenneth WDirector · 11 transactions | +25.8% | 30.3K | 17.4K | — | 5.0K |
| Sablich KimEVP, GM of U.S. · 15 transactions | +19.2% | 28.5Kas of Jun 2023 | 20.4K | — | 9.6K |
| Henderson Mary ElizabethSVP, Technical Operations · 12 transactions | — | 27.3K | 39.7K | — | 9.0K |
| Larkin FinbarSVP, Technical Operations · 10 transactions | +31.8% | 21.8Kas of Mar 2023 | 10.7K | — | 6.0K |
| Enright Patrick GDirector · 11 transactions | -5.5% | 21.4Kas of Aug 2025 | 12.9K | — | 9.3K |
| McSharry Heather AnnDirector · 13 transactions | +65.2% | 18.4K | 24.3K | — | 13.4K |
| Riedel Norbert GDirector · 12 transactions | — | 17.7K | 24.3K | — | 13.7K |
| ORiordan AnneDirector · 10 transactions | +69.9% | 16.5Kas of Aug 2025 | 12.9K | — | 2.8K |
| Gray PeterDirector · 6 transactions | +25% | 16.1Kas of Aug 2023 | 13.6K | — | 10.4K |
| Sohn Catherine A.Director · 4 transactions | +28.6% | 14.9Kas of Aug 2023 | 5.6K | — | 2.3K |
| Tovey Christopher J.EVP, COO & Managing Director E · 5 transactions | +58552% | 14.7Kas of Jul 2022 | 11.9K | — | 5.2K |
| Cook Jennifer E.Director · 11 transactions | +124.1% | 10.8Kas of Aug 2025 | 12.9K | — | 3.6K |
| Smith Mark DouglasDirector · 12 transactions | +100.2% | 9.7K | 12.9K | — | 4.7K |
| Winningham Rick EDirector · 11 transactions | +34% | 9.6K | 16.3K | — | 10.6K |
| Hamill LauraDirector · 3 transactions | — | 6.9Kas of Aug 2025 | 7.2K | — | — |
| Kennedy PatrickDirector · 4 transactions | — | 6.7Kas of Aug 2025 | 8.7K | — | — |
| Carr PatriciaSVP, Chief Accounting Officer · 51 transactions | +7.9% | 6.5K | 35.0K | — | 31.8K |
| Love Ted WDirector · 1 transaction | — | 1.5K | 1.5K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -454.3K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.